help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Erratum for Shankar, Oncologist 13 (2) 157-166.
The Oncologist, Vol. 13, No. 3, 347, March 2008; doi:10.1634/theoncologist.2007-0126erratum
© 2008 AlphaMed Press

This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shankar, A. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shankar, A. G.

The Role of Recombinant Erythropoietin in Childhood Cancer

Ananth Gouri Shankar

On page 160, there were errors in the text. Here we print the correct text.

doi: 10.1634/theoncologist.2007-0126

Study 3
A placebo-controlled, randomized study that evaluated the effect of epoetin alfa along with iron supplementation on transfusion requirements in children with sarcomas receiving intensive chemotherapy concluded that prophylactic rHuEPO significantly reduced RBC transfusion requirements [28]. In this study, although 24 children were randomized, only 20 patients were deemed evaluable. Of these 20 children, 10 each were randomly assigned to receive either epoetin alfa or a matching volume of placebo (normal saline) for 16 weeks. The dose of rHuEPO was 150 IU/kg three times per week s.c. or i.v. Compared with placebo, children randomized to receive epoetin alfa had significantly fewer RBC [p = .01] and platelet [p = .005] transfusions. However, there was no difference in the number of patients who required any RBC transfusion in the study [EPO group, 9/10; no EPO group, 10/10]. No significant toxic effects of rHuEPO were reported.





This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shankar, A. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shankar, A. G.


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl